Orphan Drug Designation in the EU Driving Innovation for Rare Diseases Read more about Orphan Drug Designation in the EU Driving Innovation for Rare Diseases By Vigilare Biopharma November 21, 2025Uncategorized
FDA Approves First Gene Therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency: A Landmark in Rare Disease Treatment Read more about FDA Approves First Gene Therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency: A Landmark in Rare Disease Treatment By Vigilare Biopharma November 15, 2024FDA